Similarly, in an ongoing clinical trial with anti-CD123 antibody-drug conjugate IMGN632, no endothelial or marrow toxicity was seen33,34 in AML or BPDCN patients, supporting acceptable safety targeting CD123. This evidence concerns the gene IL3RA and acute myeloid leukemia.